Global Lapatinib Ditosylate API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Lapatinib Ditosylate API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
Lapatinib Ditosylate API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Lapatinib Ditosylate API market is projected to reach US$ 17 million in 2034, increasing from US$ 14 million in 2022, with the CAGR of 4.4% during the period of 2024 to 2034. Demand from Research and Pharmaceutical are the major drivers for the industry.
Global key players of lapatinib ditosylate API include Novartis, Hetero, Natco Pharma, etc. The top three players hold a share over 29%. Europe is the largest market, has a share about 66%, followed by Asia Pacific, and Middle East and Africa, with share 19% and 15%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lapatinib Ditosylate API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Tecoland
Hetero
Vannsh Life Sciences
Natco Pharma
Huirui Pharma
Shengda Pharmaceutical
Shijiazhuang Dingmin Pharmaceutical Sciences
ScinoPharm Taiwan
Shandong Boyuan Pharmaceutical
Segment by Type
Lapatinib Ditosylate Hydrate
Anhydrous Lapatinib Ditosylate
Research
Pharmaceutical
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Lapatinib Ditosylate API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Lapatinib Ditosylate API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Lapatinib Ditosylate API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Lapatinib Ditosylate API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Lapatinib Ditosylate API introduction, etc. Lapatinib Ditosylate API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Lapatinib Ditosylate API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Lapatinib Ditosylate API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Lapatinib Ditosylate API market is projected to reach US$ 17 million in 2034, increasing from US$ 14 million in 2022, with the CAGR of 4.4% during the period of 2024 to 2034. Demand from Research and Pharmaceutical are the major drivers for the industry.
Global key players of lapatinib ditosylate API include Novartis, Hetero, Natco Pharma, etc. The top three players hold a share over 29%. Europe is the largest market, has a share about 66%, followed by Asia Pacific, and Middle East and Africa, with share 19% and 15%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lapatinib Ditosylate API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Tecoland
Hetero
Vannsh Life Sciences
Natco Pharma
Huirui Pharma
Shengda Pharmaceutical
Shijiazhuang Dingmin Pharmaceutical Sciences
ScinoPharm Taiwan
Shandong Boyuan Pharmaceutical
Segment by Type
Lapatinib Ditosylate Hydrate
Anhydrous Lapatinib Ditosylate
Segment by Application
Research
Pharmaceutical
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Lapatinib Ditosylate API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Lapatinib Ditosylate API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Lapatinib Ditosylate API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Lapatinib Ditosylate API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Lapatinib Ditosylate API introduction, etc. Lapatinib Ditosylate API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Lapatinib Ditosylate API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices